Sudarshan Pharma Industries Ltd Stock Price Today (NSE: SUDARSHAN)
Fundamental Score
Sudarshan Pharma Industries Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sudarshan Pharma Industries Ltd share price today is ₹24.24, up +5.48% on NSE/BSE as of 30 March 2026. Sudarshan Pharma Industries Ltd (SUDARSHAN) is a Small-cap company in the Specialty Chemicals sector with a market capitalisation of ₹634.86 (Cr). The 52-week high for SUDARSHAN share price is ₹35.19 and the 52-week low is ₹18.50. At a P/E ratio of 32.14x, SUDARSHAN is currently trading above its industry average P/E of 29.20x. The company has a Return on Equity (ROE) of 14.83% and a debt-to-equity ratio of 1.56.
Sudarshan Pharma Industries Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Sudarshan Pharma Industries Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Sudarshan Pharma Share Price Analysis: A ROCE-Focused Perspective
Specialty chemicals, a sector often characterized by niche applications and high technical barriers, are witnessing increased scrutiny for capital efficiency. This analysis examines the current Sudarshan Pharma share price of ₹25.36, focusing particularly on its Return on Capital Employed (ROCE). We will explore how this metric influences the company's competitive positioning and future prospects, based on a fundamental audit verified by Sweta Mishra.
Sudarshan Pharma Industries Ltd. currently trades at a Price-to-Earnings (PE) ratio of 32.14. A critical factor is the company's ROCE of 15.51%. ROCE is a key indicator of how effectively a company generates profit from its capital investments. While the PE ratio provides insight into market valuation, ROCE demonstrates the underlying profitability and efficiency of the business. A higher ROCE typically suggests a more efficient allocation of capital and a stronger competitive advantage.
A ROCE of 15.51% could be interpreted as a potential source of economic moat. A consistent and sustainable ROCE exceeding the company's cost of capital suggests that Sudarshan Pharma possesses some form of competitive advantage, such as specialized formulations, strong customer relationships, or efficient operations, which allow it to generate superior returns. However, further investigation is needed to understand the durability of this competitive advantage, especially when contrasted with other companies in the sector.
In comparison to sector peers like
Amal, a comprehensive management quality assessment would be necessary. For example, a review of historical capital allocation decisions, strategic investments, and the overall execution of management plans by Amal can offer valuable context. This comparative perspective, as part of our 80-parameter fundamental audit verified by Sweta Mishra, helps determine if Sudarshan Pharma's management is utilizing capital as effectively or more effectively than its competitors, ultimately influencing future Sudarshan Pharma share price.Disclaimer: This analysis is observational and for informational purposes only. It is based on publicly available data and does not constitute financial advice. This is part of an 80-parameter fundamental audit verified by Sweta Mishra.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sudarshan Pharma Industries Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SUDARSHAN across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Excellent ROCE Performance (15.51%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Revenue Growth (31.33%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (27.83% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (41.08% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (69.73% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (57.39%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Margin Pressure Concerns (4.84%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-38.07%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Elevated Debt Levels (D/E: 1.56)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (2.23x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-12.20 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Sudarshan Pharma Industries Ltd Financial Statements
Comprehensive financial data for Sudarshan Pharma Industries Ltd including income statement, balance sheet and cash flow
About SUDARSHAN (Sudarshan Pharma Industries Ltd)
Sudarshan Pharma Industries Ltd is a dynamic force within the specialty chemicals sector, crafting a diverse portfolio of high-quality chemical solutions for a multitude of industr...ies. With a strong foundation built on innovation and customer-centricity, Sudarshan specializes in the creation of advanced intermediates critical for the pharmaceutical and agrochemical sectors. Beyond these key areas, the company extends its expertise to providing bespoke chemical solutions for the coating, construction, and various other industrial applications, tailoring products to meet specific and evolving needs. Sudarshan’s commitment to research and development ensures it remains at the forefront of chemical innovation, constantly exploring new avenues to deliver enhanced performance and value to its clients. The core strength of Sudarshan Pharma Industries lies in its comprehensive manufacturing capabilities, allowing for the production of both Active Pharmaceutical Ingredients (APIs) and essential vitamins. This vertical integration provides significant advantages in terms of quality control, cost efficiency, and supply chain management. Further diversifying its offerings, Sudarshan also produces fine chemicals and solvents, serving as a reliable partner for industries requiring high-purity materials. The company's unwavering focus on adherence to stringent quality standards and regulatory compliance reinforces its position as a trusted supplier of critical chemical components. Sudarshan Pharma Industries’ expansive product range caters to a wide array of specialized applications. This includes the development and manufacturing of specialized materials for leather processing, oil field operations, and lubricant formulations. The company also provides key chemicals for the creation of high-performance paints and coatings, as well as essential additives for the paper industry. Furthermore, Sudarshan manufactures ingredients used in personal care products, alongside specialized chemicals tailored for food coloring applications. By consistently providing innovative and reliable solutions, Sudarshan Pharma Industries remains a vital partner to businesses across numerous sectors, driving growth and enabling advancement.
Company Details
Key Leadership
Corporate Events
Latest News
SUDARSHAN Share Price: Frequently Asked Questions
What is the current share price of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
As of 30 Mar 2026, 12:08 pm IST, Sudarshan Pharma Industries Ltd share price is ₹24.24. The SUDARSHAN stock has a market capitalisation of ₹634.86 (Cr) on NSE/BSE.
Is SUDARSHAN share price Overvalued or Undervalued?
SUDARSHAN share price is currently trading at a P/E ratio of 32.14x, compared to the industry average of 29.20x. Based on this relative valuation, the Sudarshan Pharma Industries Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SUDARSHAN share price?
The 52-week high of SUDARSHAN share price is ₹35.19 and the 52-week low is ₹18.50. These values are updated daily from NSE/BSE price data.
What factors affect the Sudarshan Pharma Industries Ltd share price?
Key factors influencing SUDARSHAN share price include quarterly earnings growth (Sales Growth: 31.33%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sudarshan Pharma Industries Ltd a good stock for long-term investment?
Sudarshan Pharma Industries Ltd shows a 5-year Profit Growth of 69.73% and an ROE of 14.83%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.56 before investing in SUDARSHAN shares.
How does Sudarshan Pharma Industries Ltd compare with its industry peers?
Sudarshan Pharma Industries Ltd competes with major peers in the Specialty Chemicals. Investors should compare SUDARSHAN share price P/E of 32.14x and ROE of 14.83% against the industry averages to determine competitive standing.
What is the P/E ratio of SUDARSHAN and what does it mean?
SUDARSHAN share price has a P/E ratio of 32.14x compared to the industry average of 29.20x. Investors pay ₹32 for every ₹1 of annual earnings.
How is SUDARSHAN performing according to Bull Run's analysis?
SUDARSHAN has a Bull Run fundamental score of 51.4/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SUDARSHAN belong to?
SUDARSHAN operates in the Specialty Chemicals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sudarshan Pharma Industries Ltd share price.
What is Return on Equity (ROE) and why is it important for SUDARSHAN?
SUDARSHAN has an ROE of 14.83%, which shows decent profitability but room for improvement. ROE measures how efficiently Sudarshan Pharma Industries Ltd generates profits from shareholders capital.
How is SUDARSHAN debt-to-equity ratio and what does it indicate?
SUDARSHAN has a debt-to-equity ratio of 1.56, which indicates high leverage that increases financial risk.
What is SUDARSHAN dividend yield and is it a good dividend stock?
SUDARSHAN offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Sudarshan Pharma Industries Ltd shares.
How has SUDARSHAN share price grown over the past 5 years?
SUDARSHAN has achieved 5-year growth rates of: Sales Growth 27.83%, Profit Growth 69.73%, and EPS Growth 41.08%.
What is the promoter holding in SUDARSHAN and why does it matter?
Promoters hold 57.39% of SUDARSHAN shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Sudarshan Pharma Industries Ltd.
What is SUDARSHAN market capitalisation category?
SUDARSHAN has a market capitalisation of ₹635 crores, placing it in the Small-cap category.
How volatile is SUDARSHAN stock?
SUDARSHAN has a beta of N/A. A beta > 1 suggests the Sudarshan Pharma Industries Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SUDARSHAN operating profit margin trend?
SUDARSHAN has a 5-year average Operating Profit Margin (OPM) of 4.84%, indicating the company's operational efficiency.
How is SUDARSHAN quarterly performance?
Recent quarterly performance shows Sudarshan Pharma Industries Ltd YoY Sales Growth of 31.33% and YoY Profit Growth of -38.07%.
What is the institutional holding pattern in SUDARSHAN?
SUDARSHAN has FII holding of 20.79% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Sudarshan Pharma Industries Ltd stock.